CN111094272A - Pharmaceutically acceptable salt and crystal form of OTR inhibitor and preparation method - Google Patents

Pharmaceutically acceptable salt and crystal form of OTR inhibitor and preparation method Download PDF

Info

Publication number
CN111094272A
CN111094272A CN201980004485.2A CN201980004485A CN111094272A CN 111094272 A CN111094272 A CN 111094272A CN 201980004485 A CN201980004485 A CN 201980004485A CN 111094272 A CN111094272 A CN 111094272A
Authority
CN
China
Prior art keywords
otr
inhibitor
preparation
crystal form
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980004485.2A
Other languages
Chinese (zh)
Other versions
CN111094272B (en
Inventor
杨俊然
杜振兴
王捷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111094272A publication Critical patent/CN111094272A/en
Application granted granted Critical
Publication of CN111094272B publication Critical patent/CN111094272B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provides a medicinal salt and a crystal form of an OTR inhibitor and a preparation method thereof. In particular to a medicinal salt and a crystal form of 5- (3- (3- (6-fluoronaphthalene-1-yl) azetidin-1-yl) -5- (methoxymethyl) -4H-1,2, 4-triazole-4-yl) -2-methoxypyridine serving as an OTR inhibitor and a preparation method thereof. The medicinal salt improves the free alkali dissolution degree and the physical or chemical stability of the OTR inhibitor, and has important significance for developing medicaments which are suitable for industrial production and have good biological activity.

Description

Pharmaceutically acceptable salt and crystal form of OTR inhibitor and preparation method
PCT domestic application, the specification has been published.

Claims (1)

  1. PCT domestic application, claims are published.
CN201980004485.2A 2018-06-20 2019-06-19 Pharmaceutically acceptable salt and crystal form of OTR inhibitor and preparation method Active CN111094272B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810633748 2018-06-20
CN2018106337483 2018-06-20
PCT/CN2019/091888 WO2019242642A1 (en) 2018-06-20 2019-06-19 Pharmaceutically acceptable salt and crystal form of otr inhibitor and preparation method thereof

Publications (2)

Publication Number Publication Date
CN111094272A true CN111094272A (en) 2020-05-01
CN111094272B CN111094272B (en) 2022-05-27

Family

ID=68983508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980004485.2A Active CN111094272B (en) 2018-06-20 2019-06-19 Pharmaceutically acceptable salt and crystal form of OTR inhibitor and preparation method

Country Status (3)

Country Link
CN (1) CN111094272B (en)
TW (1) TW202016091A (en)
WO (1) WO2019242642A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111474202A (en) * 2020-04-09 2020-07-31 集美大学 Internal standard liquid for analyzing metabolites in biological body fluid and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028452A1 (en) * 2003-09-22 2005-03-31 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CN101107243A (en) * 2005-01-20 2008-01-16 辉瑞有限公司 Substituted triazole derivatives as oxytocin antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884071B (en) * 2016-12-21 2021-05-14 江苏恒瑞医药股份有限公司 Condensed ring based azetidinyl triazole derivative, preparation method and application thereof in medicine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028452A1 (en) * 2003-09-22 2005-03-31 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CN101107243A (en) * 2005-01-20 2008-01-16 辉瑞有限公司 Substituted triazole derivatives as oxytocin antagonists

Also Published As

Publication number Publication date
TW202016091A (en) 2020-05-01
CN111094272B (en) 2022-05-27
WO2019242642A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
JOP20190094A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2021009476A (en) Pharmaceutical composition.
MX2007007272A (en) 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors.
PH12019502851A1 (en) New azaquinoline derivatives
NO20091596L (en) Benzoylamino Heterocyclic Compounds as Glucokinase (GLK) Activators
MX2010009163A (en) Heterocyclic urea derivatives and methods of use thereof-211.
NO20091599L (en) Chemical connections
WO2006064033A3 (en) Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
NO20085067L (en) 4,5-diphenyl-pyrimidinyl substituted carboxylic acids, processes for their preparation and use thereof as medicaments
SI2150530T1 (en) Substituted sulfonamide derivatives
MX2013008213A (en) N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl )-phenyl]-amides as bace1 and/or bace2 inhibitors.
MX2019002439A (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease.
MX2013014194A (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors.
MX2019012803A (en) New bicyclic pyrazole derivatives.
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
NO20065073L (en) New beta agonists, methods of their preparation and their use as drugs.
NO20073176L (en) New drugs for the treatment of respiratory diseases
ZA202100352B (en) Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
CN111094272A (en) Pharmaceutically acceptable salt and crystal form of OTR inhibitor and preparation method
ATE473212T1 (en) HIV-INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES
NO20084177L (en) Substituted Imidazo [2,1-B] Thiazole Compounds and Their Use for Drug Production
ATE527256T1 (en) SUBSTITUTED (OXAZOLIDINONE-5-YL-METHYL)-2- THIOPHENE CARBOXAMIDES AND THEIR USE IN THE FIELD OF BLOOD CLOTTING
NO20083508L (en) Novel enantiomerically pure beta agonists, their manufacturing mates and their use as drugs
MX2016013875A (en) Active ingredient (i) containing composition and method for preparing same.
MY179339A (en) Crystal of azole benzene derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant